This article was originally published in The Tan Sheet
Executive SummaryJoint supplement ingredients nominated by National Cancer Institute for toxicological testing due to their "widespread long-term use as a dietary supplement and inadequate data to assess safety," National Toxicology Program announces in July 16 Federal Register notice. Proposed testing includes chronic toxicity and carcinogenicity review. Trans-Resveratrol nominated for testing by the National Institute of Environmental Health Sciences based on "widespread human exposure from natural dietary sources and use of dietary supplements." Studies on potential reproductive toxicity, toxicological characterization, carcinogenicity advised. Deadline for comments on nominations due at Sept. 15...
You may also be interested in...
Laparoscopic power morcellation to remove uterine fibroids should only be performed with the use of a compatible containment system, and only on women younger than 50, the US FDA said in a newly published safety communication and draft guidance document. See what the president of the gynecologic trade group AAGL, Jubilee Brown, said about it here.
The fast-dissolving tablet will launch in early March. Its list price is not available but based on pricing for Allergan’s oral anti-CGRP Ubrelvy, ICER has said Biohaven’s rimegepant is likely to be cost-effective.
A surge in Chinese applications for clinical trials for coronavirus treatments, and a fall in patient numbers, are complicating recruitment efforts for the most promising drugs, prompting official moves to tighten study rules.